Family Practice News Digital Network The cardiac safety of rosiglitazone, a thiazolidinedione (TZD) marketed as Avandia by GlaxoSmithKline, has been mired in controversy for several years because of analyses of data showing that rosiglitazone may increase the risk of MI or death. The Food ...
Diabetes In Control One was an updated meta-analysis by Steven Nissen, MD, of the Cleveland Clinic, and colleagues, which found a significantly increased risk of MI with use of the drug , and the other was an analysis of FDA data that found a higher risk of a composite of ...
Medscape Drug therapy is often necessary to achieve blood pressure control. Diuretics, inhibitors of the renin–angiotensin system, and dihydropyridine calcium channel blockers are often used as first trio, with subsequent additions of mineralocorticoid receptor ...
MedPage Today In a post-hoc analysis of data from the BARI 2D trial, patients taking rosiglitazone had an equal likelihood of dying over 5 years as those who didn't take any drug in the thiazolidinedione (TZD) class (hazard ratio 0.83, 95% CI 0.58 to 1.18, P=0.29 ...
